Abstract
O uso de bifosfonatos não é uma contraindicação absoluta para o tratamento ortodôntico, especialmente para pacientes de baixo risco. No entanto, o resultado do tratamento ainda não é previsível em pacientes de alto risco.
Highlights
These drugs act as regulators of bone metabolism, through the inhibition of osteoclastic activity, promoting a reduction of bone resorption, mainly through the induction of apoptosis in osteoclasts and the inhibition of maturation of these cells.[1,2,6,7] In clinical terms, the overall effect of these agents is the increase in bone mass, reduction of hypercalcemia, stabilization of bone pathologies, improvement in bone strength and the risk reduction of pathological fracture.[8,9]
The use in long-term of bisphosphonates to treat osteoporosis can lead to the accumulation of the drug in the bone
The drug is released slowly during physiologic bone remodeling and in a greater degree during bone remodeling, i.e., in the processes associated with the orthodontic movement, increasing its absorption in localized ar
Summary
These drugs act as regulators of bone metabolism, through the inhibition of osteoclastic activity, promoting a reduction of bone resorption, mainly through the induction of apoptosis in osteoclasts and the inhibition of maturation of these cells.[1,2,6,7] In clinical terms, the overall effect of these agents is the increase in bone mass, reduction of hypercalcemia, stabilization of bone pathologies, improvement in bone strength and the risk reduction of pathological fracture.[8,9]. The use in long-term of bisphosphonates to treat osteoporosis can lead to the accumulation of the drug in the bone. The drug is released slowly during physiologic bone remodeling and in a greater degree during bone remodeling, i.e., in the processes associated with the orthodontic movement, increasing its absorption in localized ar-
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have